Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Recurrent/Metastatic Salivary Gland Cancers
NCT02857712Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in salivary gland cancer (SGC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Dec 2014; status: completed.
02
Drugs
axitinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT02857712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857712.